350 rub
Journal №6 for 2013 г.
Article in number:
Parkinson's disease
Keywords: Parkinson-s disease neuronal death
Authors:
N.N. Durmanov
Abstract:
It is known that one of the key events in the development of Parkinsonism is the massive loss of dopaminergic neurons of the nigrostriatal pathway, though it is still unknown whether it is the main cause or the result of the disease. Currently used drugs mostly produce symptomatic effects by affecting the dopamine metabolism, while the main task at hand is the prevention of neuron loss, the reason of which is not completely known.
Pages: 13-16
References
  1. Samii A., Nutt J.G., Ransom B.R. Parkinson-s disease // Lancet. 2004. V. 363. P. 1783-1793.
  2. Fahn S. The history of dopamine and levodopa in the treatment of Parkinson-s disease (англ.) // Mov. Disord. 2008. V. 23. Suppl 3. P. S497-508.
  3. Hughes A. J. et al. UK Parkinson-s Disease Society Brain Bank Clinical Diagnostic Criteria // J. Neurol. Neurosurg. Psychiatry. 1992. V. 55. P. 181-184.
  4. Clifford W. Shults. Lewy bodies // PNAS February 7. 2006. V. 103. № 6. Р. 1661-1668.
  5. Clayton D.F., George J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease //Trends in Neuroscience. 1998. V. 21. № 6. P. 249-254.
  6. von Coelln R., Shaida B.Th., Andrabi A., Lim K.L., Savitt J.M., Saffary R., Stirling W., Bruno K., Hess E.J., Lee M.K., Dawson V.L., Dawson T.M. Inclusion Body Formation and Neurodegeneration Are Parkin Independent in a Mouse Model of α-Synucleinopathy // J. Neurol. Sci. 2006. V. 26. № 14. P. 3685-3696. doi: 10.1523/0414-06.
  7. Ishizawa T., Matilla P., Ph.D., Davies P., Wang D., Dickson D.W. Colocalization of Tau and Alpha-Synuclein Epitopes in Lewy Bodies Colocalization of tau and alpha-synuclein epitopes in Lewy bodies // Journal of Neuropathology & Experimental Neurology. 2003. V. 62. № 4. Р. 389-397.
  8. McLean P.J., Kawamata H., Ribich S., Hyman B.T. Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations //J. Biol. Chem.2000. V. 275. № 12. Р. 8812-8816.
  9. Burré J., Sharma M., Tsetsenis T., Buchman V., Etherton M.R., Südhof T.C. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro // Science.2010. V. 329. № 5999. P. 1663-1667.
  10. Obeso J.A., Rodríguez-Oroz M.C., Benitez-Temino B. et al. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease // Mov. Disord. 2008. V. 23. Suppl 3. P. S548-559.
  11. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes f Parkinson and Huntington. Clinical, morphological and neurochemical correlations // J. Neurol. Sci. 1973. V. 20. P. 415-455.
  12. Herkenham M., Little M.D., Bankiewicz K., Yang S.C., Markey, S.P., Johannessen J.N. Selective retention of MPP_4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administra- within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study // Neuroscience. 1991. V. 40. P. 133-158.
  13. Wu D.C., Teismann P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., and Przedborski S. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydro­pyridine model of Parkinson-s disease // Proc. Natl. Acad. Sci. USA.2003. V. 100. P. 6145-6150.
  14. Lashuel H.A., Hartley D., Petre B.M., Walz T., Lansbury P.T. Neurodegenerative disease: amyloid pores from pathogenic mutations // Nature. 2002. Jul. 18. V. 418. № 6895. P. 291.
  15. Lashuel H.A., Petre B.M., Wall J., Simon M., Nowak R.J., Walz T., Lansbury P.T. Jr. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils // J. Mol. Biol. 2002. Oct 4. V. 322. № 5. P. 1089-1102.
  16. Conway K.A., Rochet J.C., Bieganski R.M., Lansbury P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct // Science. 2001. Nov. 9. V. 294(5545). P. 1346-1349.
  17. Nakaso K., Tajima N., Ito S., Teraoka M., Yamashita A., Horikoshi Y., Kikuchi D., Mochida S., Nakashima K., Matsura T. Dopamine-mediated oxidation of methionine 127 in α-synuclein- causes cytotoxicity and oligomerization of α-synuclein // PLoS One. 2013. V. 8. № 2. P. e55068.
  18. Bennett E.J., Bence N.F., Jayakumar R., Kopito R.R. Global Impairment of the Ubiquitin-Proteasome System by Nuclear or Cytoplasmic Protein Aggregates Precedes Inclusion Body Formation // Molecular Cell. 2005. V. 17. P. 351-365. February 4.
  19. Kopito R.R. Aggresomes, inclusion bodies and protein aggregation // Trends Cell Biol. 2000. V. 10. P. 524-530.
  20. Cummings C.J., Reinstein E., Sun Y., Antalffy B., Jiang Y., Ciechanover A., Orr H.T., Beaudet A.L., Zoghbi H.Y. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice // Neuron. 1999. V. 24. P. 879-892.
  21. Cummings C.J., Sun Y., Opal P., Antalffy B., Mestril R., Orr H.T., Dillmann W.H., Zoghbi H.Y. Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice // Hum. Mol. Genet. 2001. V. 10. P. 1511-1518.
  22. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C., Squitieri F., Ibanez P., Joosse M., van Dongen J.W., Vanacore N., van Swieten J.C., Brice A., Meco G., van Duijn C.M., Oostra B.A., Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonismScience.January 2003. V. 299.№ 5604. P. 256-259.
  23. Heutink P. PINK-1 and DJ-1--new genes for autosomal recessive Parkinson's disease //J. Neural Transm. Suppl. // Journal of Neural Transmission. Supplementa.2006. V. 70. № 70. P. 215-219.
  24. Smith W.W., Pei Z., Jiang H., Moore D.J., Liang Y., West A.B., Dawson V.L., Dawson T.M., Ross C.A. // Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration //Proc. Natl. Acad. Sci. U.S.A.December 2005. V. 102.№ 51. P. 18676-18681.
  25. Healy D.G., Abou-Sleiman P.M., Wood N.W. Genetic causes of Parkinson's disease: UCHL-1 //Cell Tissue Res.2005. V. 318.№ 1. P. 189-194.
  26. Illarioshkin S.N. Osnovny'e princzipy' terapii bolezni Parkinsona // Rossijskij mediczinskij zhurnal. 2004. T. 12. № 10. S. 604-608.]
  27. Needham E., Worth P. Parkinson's disease: a guide to pharmacological management // Prescriber. 2012. V. 23. Issue 5. P. 21-31.
  28. Di Stefano A., Sozio P., Cerasa L.S., Iannitelli A. L-Dopa prodrugs: an overview of trends for improving Parkinson's disease treatment // Curr. Pharm. Des. 2011. V. 17. № 32. P. 3482-3493.
  29. Tintner R., Jankovic J. Dopamine agonists in Parkinson's disease // Expert Opin Investig Drugs. 2003. V. 12(11). P. 1803-1820.
  30. Riederer P., Laux G. MAO-inhibitors in Parkinson's Disease // Exp Neurobiol. 2011. V. 20. № 1. P. 1-17.
  31. Hubsher G., Haider M., Okun M.S. Amantadine: the journey from fighting flu to treating Parkinson disease // Neurology. 2012. Apr 3. V. 78. № 14. P. 1096-1099.
  32. Isacson O., Kordower J.H. Future of cell and gene therapies for Parkinson's disease // Ann. Neurol. 2008. Dec. V. 64 Suppl 2. P. S122-38. doi: 10.1002/ana.21473.
  33. Fiandaca M.S., Bankiewicz K.S., Federoff H.J. Gene Therapy for the Treatment of Parkinson-s Disease: The Nature of the Biologics Expands the Future Indications // Pharmaceuticals. 2012. V. 5. № 6. P. 553-590.